VolitionRX Ltd(VNRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 9:10 AM ET (Korea 9/11 22:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.84 | Insider Own | 11.01% | Shs Outstand | 13.7M | Perf Week | -9.67% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 64.52% | Insider Trans | - | Shs Float | 12.2M | Perf Month | -52.46% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.38 | Inst Own | 14.33% | Short Float | 5.63% | Perf Quarter | -75.54% |
| Income | -0.03B | P/S | 2.59 | EPS this Y | 53.03% | Inst Trans | 5.54% | Short Ratio | 0.09 | Perf Half Y | -91.61% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 57.2% | ROA | -306.96% | Short Interest | 0.68M | Perf YTD | -93.35% |
| Book/sh | -2.67 | P/C | 2.28 | EPS past 3/5Y | 26.33% 13.42% | ROE | - | 52W High | -97.7% ($14.80) | Perf Year | -97.26% |
| Cash/sh | 0.15 | P/FCF | - | Sales past 3/5Y | 77.98% 164.15% | ROIC | - | 52W Low | 5.3% ($0.32) | Perf 3Y | -98.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.31% | Gross Margin | 53.07% | Volatility(W/M) | 7.36% 15.32% | Perf 5Y | -99.47% |
| Dividend TTM | - | EV/Sales | 5.53 | Sales Y/Y TTM | 86.32% | Oper. Margin | -790.23% | ATR (14) | 0.08 | Perf 10Y | -99.64% |
| Dividend Ex-Date | - | Quick Ratio | 0.3 | EPS Q/Q | 30.54% | Profit Margin | -1061.82% | RSI (14) | 28.4 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.3 | Sales Q/Q | -1.97% | SMA20 | -19.76% ($0.42) | Beta | 1.14 | Target Price | $11 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -56.94% ($0.79) | Rel Volume | 0.12 | Prev Close | $0.34 |
| Employees | 75 | LT Debt/Eq | - | EPS/Sales Surpr. | -49.78% -4% | SMA200 | -89.23% ($3.16) | Avg Volume(3M) | 7.61M | Price | $0.34 |
| IPO | 2007/4/25 | Option/Short | Yes/Yes | Trades | 1638 | Volume | 919,068 | Change | -0.58% |
Company
VNRX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧫 VolitionRX is a Belgium-based in-vitro diagnostics company developing and commercializing its proprietary Nu.Q® diagnostic platform, which measures nucleosomes in the blood. Its key indications include early cancer detection, sepsis and NET (neutrophil extracellular trap) assessment, and the veterinary diagnostics field. The company is expanding commercialization through licensing agreements with global diagnostics majors such as Werfen and Hologic, and is a micro-cap stock listed on NYSE American.
Over the past 1 year, on the lower side
98% below its 1-year high.
VNRX has weak earning power
-790.23% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -98.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 14.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $6M.
VNRX $6M PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is VNRX?
VNRX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of VNRX?
The market cap of VNRX is approximately $6M, ranking 5,626 within its sector.
What is the 52-week high and low for VNRX?
VNRX has recorded a 52-week high of $14.80 and a low of $0.32.
